Moors & Cabot Inc. Makes New $1.79 Million Investment in Tenet Healthcare Corporation $THC

Moors & Cabot Inc. bought a new position in Tenet Healthcare Corporation (NYSE:THC – Free Report) during the third quarter, according to its most recent filing with the SEC. The firm bought 7,013 shares of the company’s stock, valued at approximately $1,792,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. V Square Quantitative Management LLC bought a new position in shares of Tenet Healthcare in the third quarter valued at $26,000. Mather Group LLC. grew its stake in shares of Tenet Healthcare by 126.9% in the 3rd quarter. Mather Group LLC. now owns 118 shares of the company’s stock worth $30,000 after acquiring an additional 66 shares in the last quarter. MADDEN SECURITIES Corp purchased a new stake in shares of Tenet Healthcare in the third quarter valued at about $38,000. Trust Co. of Vermont purchased a new stake in shares of Tenet Healthcare in the second quarter valued at about $37,000. Finally, Fortitude Family Office LLC lifted its position in shares of Tenet Healthcare by 52.1% during the third quarter. Fortitude Family Office LLC now owns 222 shares of the company’s stock valued at $57,000 after purchasing an additional 76 shares in the last quarter. Institutional investors own 95.44% of the company’s stock.

Insider Activity at Tenet Healthcare

In related news, Director J. Robert Kerrey sold 12,010 shares of Tenet Healthcare stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $263.72, for a total value of $3,167,277.20. Following the completion of the transaction, the director directly owned 4,794 shares in the company, valued at approximately $1,264,273.68. The trade was a 71.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Nadja West sold 1,152 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $258.80, for a total transaction of $298,137.60. Following the sale, the director directly owned 23,653 shares in the company, valued at $6,121,396.40. The trade was a 4.64% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 99,462 shares of company stock worth $27,081,234 in the last ninety days. Insiders own 0.97% of the company’s stock.

Tenet Healthcare Trading Up 0.1%

Shares of Tenet Healthcare stock opened at $286.34 on Monday. The stock has a market capitalization of $22.79 billion, a P/E ratio of 8.30, a P/E/G ratio of 1.53 and a beta of 1.20. Tenet Healthcare Corporation has a 52-week low of $157.58 and a 52-week high of $301.44. The company has a debt-to-equity ratio of 1.76, a quick ratio of 1.52 and a current ratio of 1.58. The stock’s 50-day simple moving average is $267.83 and its 200 day simple moving average is $224.88.

Tenet Healthcare (NYSE:THC – Get Free Report) last issued its earnings results on Thursday, October 29th. The company reported $6.64 earnings per share for the quarter, topping analysts’ consensus estimates of $4.68 by $1.96. The firm had revenue of $6.28 billion during the quarter, compared to analyst estimates of $5.49 billion. Tenet Healthcare had a net margin of 13.09% and a return on equity of 28.22%. The company’s quarterly revenue was up 6.5% on a year-over-year basis. During the same quarter last year, the business earned $3.70 earnings per share. As a group, research analysts anticipate that Tenet Healthcare Corporation will post 22.32 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Tenet Healthcare in a report on Friday, October 2nd. BMO Capital Markets started coverage on shares of Tenet Healthcare in a research note on Tuesday, September 22nd. They issued a “market perform” rating and a $265.00 price objective for the company. UBS Group lifted their target price on shares of Tenet Healthcare from $288.00 to $308.00 and gave the stock a “buy” rating in a research report on Monday, July 27th. TD Cowen boosted their target price on Tenet Healthcare from $233.00 to $263.00 and gave the stock a “buy” rating in a research note on Monday, July 27th. Finally, Bank of America boosted their target price on Tenet Healthcare from $290.00 to $295.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Nineteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $296.65.

View Our Latest Research Report on Tenet Healthcare

Tenet Healthcare Profile

(Free Report)

Tenet Healthcare Corporation is a U.S.-based healthcare services company that operates acute care hospitals and provides related inpatient and outpatient services. Its hospitals offer services across areas such as emergency care, surgery, imaging and specialty treatment. Through its subsidiary United Surgical Partners International (USPI), Tenet also operates ambulatory surgery centers and surgical hospitals, providing outpatient surgical and procedural care. The company’s Conifer Health Solutions business provides revenue cycle management and other administrative services to healthcare providers.

See Also

Want to see what other hedge funds are holding THC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tenet Healthcare Corporation (NYSE:THC – Free Report).

Institutional Ownership by Quarter for Tenet Healthcare (NYSE:THC)

Receive News & Ratings for Tenet Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenet Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.